Brokerages Set Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Target Price at $46.17

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) has been given a consensus recommendation of “Moderate Buy” by the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $39.80.

A number of research firms have recently weighed in on TVRD. HC Wainwright assumed coverage on Tvardi Therapeutics in a research report on Monday, June 8th. They set a “buy” rating and a $9.00 price objective on the stock. BTIG Research reaffirmed a “buy” rating and set a $15.00 price objective on shares of Tvardi Therapeutics in a report on Wednesday, April 1st. Wall Street Zen downgraded shares of Tvardi Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 4th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Tvardi Therapeutics in a research note on Friday, April 10th.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. purchased a new position in Tvardi Therapeutics in the second quarter valued at about $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $43,000. Headlands Technologies LLC purchased a new position in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $80,000. New York State Common Retirement Fund purchased a new position in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $92,000. Finally, Arax Advisory Partners boosted its position in Tvardi Therapeutics by 277.2% during the fourth quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock worth $36,000 after acquiring an additional 6,173 shares during the last quarter. 44.66% of the stock is owned by hedge funds and other institutional investors.

Tvardi Therapeutics Stock Down 2.6%

Shares of NASDAQ TVRD opened at $2.64 on Wednesday. Tvardi Therapeutics has a 52-week low of $2.61 and a 52-week high of $43.65. The business’s 50 day moving average is $3.31 and its two-hundred day moving average is $3.75. The firm has a market cap of $24.76 million, a price-to-earnings ratio of -0.85 and a beta of 0.33.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.08). Analysts anticipate that Tvardi Therapeutics will post -2.39 EPS for the current fiscal year.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.